MI-LINEAGE-LOGISTICS
19.5.2022 08:02:12 CEST | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today unveiled its South East Superhub in Peterborough, Cambridgeshire, just 70 miles from Central London and 120 miles from its Northern Superhub in Heywood near Manchester.
Lineage completed the new, fully-automated warehouse expansion with an additional 45,000 pallet positions in Peterborough, bringing the total capacity to nearly 71,000 pallets today. The expanded warehouse creates a strategically-positioned South East Superhub, which will serve both retail and foodservice customers with unique supply chain requirements. This 35-metre tall expansion will feature some of the world’s most sophisticated automation and refrigeration technology, helping to reduce energy consumption and the environmental impact of food distribution.
“We are investing in the future of food supply chain across Europe, using the latest technology, data analytics and green solutions to help feed the world in the most efficient way possible. Our Peterborough Superhub is the latest demonstration of Lineage’s ongoing commitment to our UK customers and an indication of our aim to be a leader in this crucial sector across Europe,” said Harld Peters, President of Europe at Lineage.
Lineage is committed to achieving net zero greenhouse gas emissions, and achieving this goal goes hand in hand with innovation, which is why the South East Superhub has the latest data-driven solutions to optimize energy use, with precision cooling cycles and full automation to minimize energy leakage.
The combination of traditional capacity in Lineage’s existing facilities on the site, combined with the expansion’s automated design, will enable maximum flexibility and a highly-customized solution for customers. This investment brings Lineage’s total automated warehouse count in the UK to six, with a total of 335,000 automated pallet positions.
The South East Superhub launch follows the expansion of Lineage’s Northern Superhub near Manchester, in September 2021, which added 22,000 pallet positions in a state-of-the-art facility. Together, these warehouses serve the main population and economic centres in England, and complement Lineage’s other facilities in the UK, ensuring that food service and retail customers across the country have access to reliable, sustainable and efficient warehouses to store cold and frozen food on the way to the final customer.
“At a time of supply chain volatility, Lineage’s Peterborough Superhub will play a key role in ensuring a reliable food supply in the most densely populated part of the UK,” said Tim Moran, Lineage’s Senior Vice President for Operations in Europe. “Additionally, we’ll be able to meet growing customer demand from both online and conventional grocery sales, an accelerated trend coming out of the COVID-19 pandemic as well as the disruption of supplies stemming from Russia’s invasion of Ukraine.”
Lineage Logistics is one of the largest temperature-controlled logistics providers in the UK. At the same time, Lineage has been expanding its network across Europe in recent years, creating a one-stop-shop solution for customers across the continent. This reduces the complexity of moving food between countries, reduces food waste and makes the distribution of food and goods requiring cold storage more efficient.
“Our large expansions in these two critical logistics hubs highlight Lineage’s commitment to adapting to our customers’ demands as consumer expectations shift in the UK and around the globe,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage. “We are, and have always been, 100% focused on our customers and their extended supply chains, and we are pleased to make these significant investments, create more than 230 much-needed jobs and provide expanded access to our next-generation cold storage network.”
About Lineage Logistics
Lineage Logistics is one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was a 2022 U.S. Best Managed Company, No. 3 in the 2022 CNBC Disruptor 50 list, No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com )
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006078/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
